Hsbc Holdings PLC purchased a new stake in Phreesia, Inc. (NYSE:PHR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 87,903 shares of the company's stock, valued at approximately $910,000. Hsbc Holdings PLC owned 0.14% of Phreesia as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in PHR. EverSource Wealth Advisors LLC lifted its holdings in Phreesia by 1,119.8% during the first quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the company's stock valued at $27,000 after purchasing an additional 3,001 shares in the last quarter. Van ECK Associates Corp increased its stake in shares of Phreesia by 78.7% during the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company's stock worth $42,000 after purchasing an additional 1,102 shares in the last quarter. New York State Teachers Retirement System acquired a new position in shares of Phreesia during the 1st quarter worth about $44,000. Rockefeller Capital Management L.P. raised its position in shares of Phreesia by 354.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company's stock worth $47,000 after purchasing an additional 2,149 shares during the last quarter. Finally, Allworth Financial LP acquired a new position in shares of Phreesia during the 2nd quarter worth about $58,000. Hedge funds and other institutional investors own 92.10% of the company's stock.
Phreesia Price Performance
NYSE:PHR opened at $11.81 on Wednesday. Phreesia, Inc. has a one year low of $7.77 and a one year high of $31.83. The stock has a market cap of $730.00 million, a PE ratio of 78.73 and a beta of 0.85. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a 50 day moving average price of $11.14 and a 200 day moving average price of $10.48.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on PHR. Wells Fargo & Company reiterated an "equal weight" rating and issued a $9.00 price objective (down from $15.00) on shares of Phreesia in a report on Wednesday, May 20th. Weiss Ratings raised Phreesia from a "sell (d)" rating to a "sell (d+)" rating in a report on Monday, July 20th. Canaccord Genuity Group decreased their target price on Phreesia from $22.00 to $16.00 and set a "buy" rating on the stock in a research report on Thursday, May 28th. Citigroup reaffirmed a "market perform" rating on shares of Phreesia in a research note on Friday, May 29th. Finally, Truist Financial boosted their price target on Phreesia from $11.00 to $12.00 and gave the stock a "hold" rating in a research report on Thursday, May 28th. Nine research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Phreesia presently has a consensus rating of "Hold" and a consensus target price of $16.65.
View Our Latest Research Report on PHR
About Phreesia
(
Free Report)
Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.
Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.
See Also
Want to see what other hedge funds are holding PHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phreesia, Inc. (NYSE:PHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Phreesia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.
While Phreesia currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.